Tenderwize
Retour à la recherche

Tocilizumab Discount Agreements (Biologika)

Techniker Krankenkasse·Hamburg, Germany·Deadline Oct 30, 2026 · 65 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-27 - Tocilizumab

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

30 / 100

Facteurs de risque

The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...

No guaranteed volume or exclusivity; expected volumes might be lower than in exclusive contracts.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Conclusion of discount agreements for Tocilizumab
  • Supply of Tocilizumab to insured persons
Afficher le résumé complet

Open-House procedure for concluding discount agreements (Rabattverträge) for the active substance Tocilizumab with all eligible pharmaceutical entrepreneurs, as per § 130a Abs. 8 SGB V. The contract period is 12 months starting 01.11.2025, ending 31.10.2026. The lead buyer is Techniker Krankenkasse, with participating health insurance funds HEK, hkk, and KKH.

Risques

The procedure is explicitly not a public procurement under EU directives; legal recourse is via social courts, not proc...

No guaranteed volume or exclusivity; expected volumes might be lower than in exclusive contracts.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in § 4 Abs. 18 AMG for the offered medicinal product
  • Must have a valid marketing authorization for Tocilizumab according to § 21 Abs. 1 Satz 1 AMG

Eligibility

  • Must submit a self-declaration (Anlage 4) confirming eligibility and reliability

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Tocilizumab Discount Agreements (Biologika)

Conclusion of pharmaceutical discount agreements for Tocilizumab via open-house procedure.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Oct 2025 - Oct 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Oct 30, 2026

Détails de la procédure

Date de publication
14 Sep 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
601421-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3